MOTS-c vs. SHLP2 and Humanin: A Comparative Analysis in Longevity and Metabolic Regulation
MOTS-c stands out among mitochondrial-derived peptides (MDPs) like SHLP2 and humanin as the most potent and well-characterized regulator of metabolism and healthspan, with robust evidence for enhancing insulin sensitivity, improving mitochondrial function, and promoting longevity through metabolic and anti-inflammatory pathways. While humanin excels in neuroprotection and hypothalamic signaling, and SHLP2 shows promise in mitochondrial resilience, MOTS-c uniquely functions as a systemic metabolic regulator and exercise mimetic, making it a leading candidate for treating age-related metabolic diseases.
What the AI assistants say
AI assistants agree that MOTS-c, humanin, and SHLP2 are key mitochondrial peptides with roles in aging and metabolism. They highlight MOTS-c’s activation of AMPK and its potential as an exercise mimetic, noting its effects on glucose uptake, insulin sensitivity, and mitochondrial biogenesis. Humanin is consistently described as neuroprotective and linked to longevity, particularly through its role in the hypothalamus and higher levels in centenarians. SHLP2 is acknowledged as less studied but potentially involved in stress response and mitochondrial protection. However, AI assistants diverge in their emphasis: some place greater weight on SHLP2’s emerging roles, while others underemphasize the distinct mechanistic pathways—particularly the brain-centric signaling of humanin versus the peripheral metabolic actions of MOTS-c. Notably, AI responses often conflate the evidence levels across peptides, presenting SHLP2 as more clinically relevant than supported by current data.
What the research actually shows
MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial genome that functions as an endogenous AMPK agonist, directly activating AMP-activated protein kinase—a master regulator of cellular energy homeostasis [1]. This activation promotes glucose uptake, fatty acid oxidation, and mitochondrial biogenesis, mimicking the metabolic benefits of exercise and calorie restriction [8]. In high-fat diet-fed mice, MOTS-c administration significantly improves insulin sensitivity, reduces body weight gain, and enhances glucose tolerance, with one study showing a 30–40% reduction in glucose area under the curve compared to controls [5]. These effects are mediated through enhanced GLUT4 translocation in skeletal muscle, the primary target organ [1]. Notably, MOTS-c levels decline with age, and restoring them in middle-aged mice improves metabolic healthspan and reduces systemic inflammation [8], underscoring its role in healthy aging.
In contrast, humanin—discovered earlier than MOTS-c—functions primarily through neuroprotection and central nervous system signaling. It circulates at high physiological levels and has been shown to protect neurons from amyloid-beta toxicity and inhibit apoptosis [3]. Landmark experiments demonstrated that infusing humanin into the third ventricle of rats near the hypothalamus dramatically improved insulin action and suppressed hepatic glucose production, revealing a direct brain-mitochondria axis in metabolic regulation [3]. This hypothalamic signaling mechanism is distinct from MOTS-c’s peripheral action. Humanin levels decline with age, but centenarians and their offspring exhibit higher levels, suggesting a genetic and functional link to longevity [8]. A specific mutation in the humanin gene found in centenarians is associated with resistance to Alzheimer’s disease, further implicating it in neurodegenerative protection [10].
SHLP2, while sharing sequence homology with humanin, exhibits different biological functions. It is involved in maintaining mitochondrial membrane potential and protecting against oxidative stress [8]. It inhibits apoptosis and promotes cell survival under stress, suggesting a role in cellular resilience during aging [8]. However, unlike MOTS-c and humanin, SHLP2 lacks strong evidence for direct metabolic regulation or insulin sensitivity enhancement. Its effects are more focused on mitochondrial integrity and anti-apoptotic activity, with limited data on systemic metabolic control or longevity outcomes [8]. While SHLP2 levels also decline with age, its functional significance in aging and disease remains less clear compared to the well-documented roles of MOTS-c and humanin [8].
The evidence base further differentiates these peptides. MOTS-c has high-level support from multiple animal studies and emerging human data, including phase 1 clinical trials assessing safety and pharmacokinetics [5]. CohBar is developing an MOTS-c analog for non-alcoholic steatohepatitis (NASH), a condition rooted in metabolic dysfunction [10]. Humanin also has strong evidence, with genetic associations in longevity and neuroprotection, as well as animal and human studies linking it to reduced neurodegeneration [3, 8]. SHLP2, by contrast, remains at a preliminary research stage, with moderate evidence primarily from in vitro and animal models, and no clinical trials reported to date.
Where the AI consensus and the research diverge
AI assistants often present SHLP2 as a more balanced or equally promising candidate for metabolic and longevity applications, a view not supported by current research. The corpus-grounded analysis shows that SHLP2 lacks the robust evidence for metabolic regulation seen in MOTS-c and the neuroprotective longevity links of humanin. Furthermore, AI responses frequently conflate the mechanisms: while MOTS-c acts peripherally via AMPK and glucose metabolism, humanin acts centrally via hypothalamic signaling. This distinction is critical but often blurred in AI summaries. The research confirms that MOTS-c is the most advanced in terms of therapeutic potential for metabolic diseases, while humanin’s strength lies in neuroprotection, and SHLP2 remains a promising but underexplored candidate.
Bottom line: MOTS-c is the most well-supported mitochondrial peptide for metabolic regulation and longevity, with strong evidence for improving insulin sensitivity, reducing obesity, and enhancing mitochondrial function, while humanin excels in neuroprotection and hypothalamic signaling, and SHLP2 remains less characterized with a focus on mitochondrial resilience rather than systemic metabolism.
References
- Age later health span, life span, and the new science of — Nir Barzilai, M D
- Hallmarks of aging_ an expanding universe
- Handbook of Biologically Active Peptides
- Life Force
- Life Span Extension_ Single-Cell Organisms to Man
- Mitochondria and the future of medicine the key to — Lee Know, ND
- NAD⁺ metabolism and the control of energy homeostasis – a balancing act between mitochondria and the nucleus
- Peptide Protocols Volume One — William A Seeds MD
Continue your research
Part of our MOTS-c: Comparisons & Stacks guide.
- How does MOTS-c compare to other mitochondrial-targeted peptides like SS-31 or Z-10 in terms of metabolic and anti-aging effects?
- In what ways does MOTS-c differ from metformin or GLP-1 agonists in its mechanism of action and side effect profile?
- How does MOTS-c compare to caloric restriction or exercise in enhancing mitochondrial function and metabolic health?
Related topics:
- Does MOTS-c influence mitochondrial biogenesis through PGC-1α or other transcription factors, and what evidence supports this?
- How does MOTS-c interact with mitochondrial pathways to modulate cellular energy homeostasis and reduce oxidative stress?
- What role does MOTS-c play in activating AMPK and inhibiting mTOR signaling, and how does this influence longevity pathways?